WuXi AppTec strengthens gene therapy offerings with OXGENE acquisition
WuXi AppTec has concluded the acquisition of UK-based contract research and development organisation OXGENE to boost its cell and gene…
02 Mar 2021
CRUK teams up with Teon to trial first-in-class cancer drug
Cancer Research UK (CRUK) has signed a clinical development collaboration with California-based Teon Therapeutics. Teon’s work focuses on developing a portfolio of immunotherapies for cancer that modulates and antagonises metabolic…
01 Mar 2021
Takeda to sell diabetes products portfolio to Teijin Pharma for $1.25bn
Takeda Pharmaceutical Company has signed an agreement to sell four non-core type 2 diabetes products in Japan to Teijin Pharma for JPY133bn ($1.25bn). The company will divest the assets, marketing…
26 Feb 2021
Grace to expand pharma portfolio with Albemarle’s business acquisition
US-based company W R Grace is set to expand its pharma portfolio with the acquisition of Albemarle’ Fine Chemistry Services business (FCS) for about $570m. As part of a definitive…
26 Feb 2021
Veteran investor Dr Robert Glassman talks life sciences, immunotherapy and Umoja
Seattle-based pre-clinical biotech Umoja Biopharma aims to revolutionise immunotherapy by retooling the patient’s immune system in vivo. Based on the pioneering work of Seattle Children’s Research Institute and Purdue University,…
26 Feb 2021
Merck signs agreement to buy Pandion Therapeutics for $1.85bn
Merck has agreed to acquire biotechnology company Pandion Therapeutics for approximately $1.85bn to expand its portfolio of autoimmune disease-targeting candidates. Under the agreement, Merck will initiate a tender offer through…
24 Feb 2021
Targeting immune diseases: Longwood Fund founds ImmuneID with $17m financing
Precision immunology company ImmuneID has launched with $17m in funding. The financing round was led by founding investor Longwood Fund; other investors participating in the round include XFund and Arch…